BIOCRATES Life Sciences AG Details

BIOCRATES Life Sciences AG

Company Profile:

The strategy of Biocrates is focused on the discovery and validation of new biomarkers for early disease detection, which will ultimately result in a new range of diagnostics, e.g., for diabetes mellitus, kidney disease, sepsis, stroke, and cancer. Biocrates has screened and identified meaningful biomarkers for these diseases and has already successfully developed the world’s first metabolomics-based research kit.

The other major area of growth for Biocrates is the field of companion diagnostics, leveraging the company’s unique technology for the benefit of partnering research organizations. The purpose of companion diagnostics is to be better able to stratify patients by drug efficacy and safety, paving the way for personalized medicine.

 

Key Products:

Thanks to its many years of experience in contract research for different pharmaceutical, biotech, and nutritional companies, Biocrates combines a thorough understanding of customer needs with a unique expertise in interpreting the biological pathways behind specific biomarker patterns.

 

Biocrates has developed a standardized, quality-controlled, fully-integrated technology platform for targeted metabolomics. Targeted metabolomics is the systematic identification and quantification of endogenous metabolites in bodily fluids and tissues. Quantitative biomarker discovery or “targeted metabolomics” is the quickest and most cost-effective way of identifying and quantifying biomarkers, which is why we have a decisive advantage in biomarker discovery and diagnostics development.

Website:
www.biocrates.com